WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407834
Description: YD277 is a novel small molecule derived from ML264, a KLF5 inhibitor that elicits cytotoxic effects in colon cancer cell lines. Krüpple-like factor 5 (KLF5) is a promising therapeutic target for TNBC. YD277 significantly induced G1 cell cycle arrest and apoptosis in MDA-MB-231 and MDA-MB-468 TNBC cells, independent of KLF5 inhibition. YD277 also reduced the protein expression levels of Cyclin D1, Bcl2 and Bclxl and promoted the expression of p21 and p27. YD277 (15 mg/kg) significantly suppressed the growth of MDA-MB-231 tumor xenografts in nude mice. These findings indicate that YD277 is a promising chemotherapeutic candidate for TNBC. Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcomes
MedKoo Cat#: 407834
Chemical Formula: C22H30ClN3O4
Exact Mass: 435.1925
Molecular Weight: 435.949
Elemental Analysis: C, 60.61; H, 6.94; Cl, 8.13; N, 9.64; O, 14.68
Synonym: YD277; YD-277; YD 277.
IUPAC/Chemical Name: tert-butyl (E)-4-(2-(3-(3-chlorophenyl)acrylamido)-N-methylacetamido)piperidine-1-carboxylate
InChi Key: QLZYWUJZDBTGDC-CMDGGOBGSA-N
InChi Code: InChI=1S/C22H30ClN3O4/c1-22(2,3)30-21(29)26-12-10-18(11-13-26)25(4)20(28)15-24-19(27)9-8-16-6-5-7-17(23)14-16/h5-9,14,18H,10-13,15H2,1-4H3,(H,24,27)/b9-8+
SMILES Code: O=C(N1CCC(N(C(CNC(/C=C/C2=CC=CC(Cl)=C2)=O)=O)C)CC1)OC(C)(C)C
Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcomes
1: Chen Z, Wu Q, Ding Y, Zhou W, Liu R, Chen H, Zhou J, Feng J, Chen C. YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway. Theranostics. 2017 Jun 11;7(8):2339-2349. doi: 10.7150/thno.17555. eCollection 2017. PubMed PMID: 28740556; PubMed Central PMCID: PMC5505065.